Download Current CV/Bio

CURRICULUM VITAE
Name:
Constantine Nicholas Aroney A.M., MBBS, MD, FRACP.
Associate Professor of Medicine, University of Queensland,
Director of Cardiology Services, Holy Spirit Northside Hospital, Brisbane.
Senior Visiting Cardiologist, Prince Charles Hospital, Brisbane.
Address:
5/166 Oxlade Drive,
New Farm, Brisbane,
Q'ld, 4005.
Tel: 3358-6695.
Level 3, Holy Spirit Northside Hospital,
Rode Rd, Chermside, 4032.
Tel: 3861-5522
Fax: 3861-5622
Mobile: 0409-177752
Date of Birth:
18th October 1956.
Place of Birth: Brisbane, Australia.
Marital Status: Married, 4 children.
Education:
1969-1973: Church of England Grammar School, Brisbane.
1979: MBBS (Q'ld) with distinctions in medicine and surgery.
1985: ECFMG (USA).
1986: FRACP.
1987-9 : Fellow, Harvard Medical School, Boston USA
1991: MD (Q'ld).
2005: FCSANZ
Memberships: 1979: President, University of Queensland Medical Society.
1986: Fellow, Royal Australasian College of Physicians.
1987: Affiliate Member, American College of Cardiology.
1987: Member, Paul Dudley White Society, Boston, USA.
1989: Member, Brisbane Angioplasty Group.
1990-05: Member, Cardiac Society of Australia and New Zealand.
2000: Founding Member, Asian Pacific Society of Interventional
Cardiology
2005: Foundation Fellow, Cardiac Society of Australia
and New Zealand
Awards:
1976: National AMSA-AMA Award (student research grant
for publ #1)
1985: National Finalist of Advanced Trainees Research Presentations
of the Royal Australian College of Physicians.
1986: Cardiac Society Travel Award for Queensland to the American
Heart Association Meeting, Dallas, Texas, USA.
1987-8: National Heart Foundation of Australia Overseas Clinical
Fellowship to Harvard Medical School, Boston, USA.
1998: Research Grant: The Prince Charles Hospital Foundation.
2000: Research Grant: The Prince Charles Hospital Foundation.
2007: Member of the Order of Australia (for service to medicine in the
field of cardiology and to the Heart Foundation and Cardiac
Society of Australia and NZ)
2010: Heart Foundation Honoured Contributor
Residencies:
Year
Position
Location
1980
1981
1982
1983
1984
1985
1986
- June 1987
Resident
Resident
Resident
Medical Registrar
Cardiology Registrar
Cardiology Registrar
Cardiology Registrar
Cardiology Registrar
Royal Brisbane Hospital
Royal Brisbane Hospital
Royal Brisbane Hospital
Royal Hobart Hospital
Royal Hobart Hospital
Royal Brisbane Hospital
Prince Charles Hospital
Prince Charles Hospital
Fellowships:
July 1987 - July 1989:
Clinical and Research Fellow, Harvard Medical School and Massachusetts General
Hospital, Boston, MA, USA.
Hospital and University Positions:
July 1989 - July 1990: Locum Cardiologist, The Prince Charles Hospital.
July 1990 - February 1991: Locum Director of Cardiology, Royal Brisbane Hospital.
1991-8: Senior Lecturer, Department of Medicine, University of Qld.
1991 – 2005: Senior Staff Cardiologist and Clinical Director Coronary Care Unit,
The Prince Charles Hospital, Chermside, Brisbane (half-time 2001-2005).
2000-3:
PhD Supervisor, E Strodl, Uni Qld (see publication #46)
2007-10: Honorary Emeritus Consultant in Cardiology, Prince Charles Hospital
Current
1998- Associate Professor, Department of Medicine, University of Qld.
2001- Foundation member, Qld Cardiology
2001- Director, Cardiology Services, Holy Spirit Northside Hospital
2010-
Senior Visiting Cardiologist, Prince Charles Hospital
Medical Licence Number
MED0001348683
National Committees:
1995-6: Chairman, Interventional Working Group, Cardiac Society
of Australia and New Zealand.
1996-03: Member, National PTCA Database Committee,
National Heart Foundation.
1996-7: Member, Quality of Care and Health Outcome Committee
of the NHMRC (Management of Unstable Angina).
1996-00: Member, Relatives Values Study Committee, CSANZ.
1997-00: Member, Consensus Group on Procedural Items - Relative
Value Study of the MBS.
1998:
Member, Cardiac Disease Working Group of the National
Health Priority Committee, Commonwealth Health Dept.
1999-04: Chairman, Organizing Committee, 2004 CSANZ National
Scientific Meeting.
1999-01: Chairman, Interventional Working Group, CSANZ.
1999-01: Deputy Chairman, Medical Issues Committee, National Heart
Foundation of Australia.
1996-2008: Member, Scientific Committee, CSANZ
2001-4: Chairman, Clinical Issues Committee, National Heart
Foundation of Australia.
2007-9: Member, National Prescribing Service Acute Coronary
Syndrome Reference Group
2007-9: Member, Heart Foundation National Meeting 2009,
Scientific Committee
2007-9: National ACS Implementation Forum (Heart Foundation)
2008-9: Member Scientific Committee, Heart Foundation 50 year
Anniversary Conference
2008-10: Member DMACS Project, National Prescriber Service
2001-2011: Member, Clinical Issues Committee, National Heart
Foundation of Australia.
1999-:2014: Co-Chairman, Writing Group, Acute Coronary Syndrome
Management Guidelines, National Heart Foundation
2014-:
Editorial Board Member: Heart, Lung and Circulation
Local and State Committees:
1989 - 04
1993-95
Medical advisory committee - Qld branch, National Heart Foundation.
Advisory committee of Rotary District 9600 Centre for Cardiovascular
Research, Griffith University.
1994-6
Postgraduate medical education committee - PCH.
1994 -04
Coronary Care Unit Management Team - PCH.
1994-02
Cardiac Rehabilitation Management Team - PCH.
1994-6
Casemix Committee - PCH.
1997-02
Cardiac Divisional Management Committee - PCH
Research and Ethics Committee - PCH.
Cardiac Health Outcomes Reference Group (associated with Brisbane
North Division of General Practice)
1990-2
Secretary, Queensland Branch, Cardiac Society of Australia and NZ.
1997-2008
Chairman, Queensland Branch, Cardiac Society of Australia and NZ.
2008-2010
Steering Committee – Multicentre drug use evaluation in hospitals –
Discharge management of acute coronary syndromes (DMACS) in
association with the National Prescribing Service
2004-10
Qld Health Reference Group, National Heart Foundation
2004-2012
Medical Advisory Committee, Holy Spirit Northside Hospital
Hospital Committees:
2001-2009 Chairman, Cardiac Services, Holy Spirit Northside Hospital.
2009- Radiation Safety Committee, Holy Spirit Northside Hospital
Publications:
1.
C Mitchell, B Emmerson, C Aroney. Prevalence of respiratory morbidity in Brisbane
waterside workers. Med J Aust 1981; 2:139-141. (research when a medical student)
2.
CN Aroney, MR Nicholson, JE Shevland. Echocardiographic features of a mediastinal
pancreatic pseudocyst. Br Heart J 1985; 53:571-573.
3.
C Aroney, F Khafagi, C Boyle, N Bett. Peripartum Cardiomyopathy: Echocardiographic
features in five cases. Am J Ob Gynecol 1986; 155:103-106.
4.
CN Aroney, JHN Bett, D Radford. Familial idiopathic restrictive cardiomyopathy.
Aust NZ J Med 1988; 18:877-78.
5.
CN Aroney, TD Ruddy, RH Dighero, MA Fifer, CA Boucher, IF Palacios.
Differentiation of restrictive cardiomyopathy from pericardial constriction: Assessment
of diastolic function by radionuclide angiography. J Am Coll Cardiol 1989; 13:100714.
6.
CN Aroney, HC Herrmann, MJ Semigran, GW Dec, MA Fifer. Linearity of the endsystolic pressure-volume relation in patients with severe heart failure. J Am Coll Cardiol
1989; 14:127-34.
7.
CN Aroney, MJ Semigran, GW Dec, CA Boucher, MA Fifer. Inotropic effect of
nicardipine in patients with heart failure: Assessment by left ventricular end-systolic
pressure-volume analysis. J Am Coll Cardiol 1989; 14:1331-8.
8.
MA Fifer, CN Aroney, MJ Semigran, HC Herrmann, GW Dec, CA Boucher. Techniques
for assessing inotropic effects of drugs in patients with heart failure: Application to the
evaluation of nicardipine. Am Heart J 1990; 119:451-6.
9.
CN Aroney. Assessment of left ventricular systolic and diastolic function in patients
with heart failure: methods, validation and applications. MD Thesis - University of
Queensland, 1991.
10.
CN Aroney, MJ Semigran, GW Dec, CA Boucher, MA Fifer. Left ventricular diastolic
function in patients with left ventricular systolic dysfunction due to coronary artery
disease: Effect of Nicardipine. Am J Cardiol 1991; 67:823-9.
11.
MJ Semigran, CN Aroney, HC Herrmann, GW Dec, CA Boucher, MA Fifer. Effects of
atrial natriuretic peptide on myocardial contractile and diastolic function in patients with
heart failure. J Am Coll Cardiol 1992; 20:98-106.
12.
KT McKenna, PT McEniery, F Maas, CN Aroney, JHN Bett, J Cameron, P Garrahy, G
Holt, KF Hossack. Clinical results and quality of life after percutaneous transluminal
coronary angioplasty: a preliminary report. Cathet Cardiovasc Diagn 1992; 27:89-94.
13.
KT McKenna, PT McEniery, F Maas, CN Aroney, JHN Bett, J Cameron, G Holt, KF
Hossack. Percutaneous transluminal coronary angioplasty: clinical and quality of life
outcomes one year later. Aust NZ J Med 1994; 24:15-21.
14.
L Carey, J Cameron, C Aroney, N Bett, G Holt, N Mahononda, P McEniery. Experience
with the Gianturco-Roubin stent for abrupt vessel closure complicating percutaneous
transluminal coronary angioplasty. Aust NZ J Med 1994; 24:31-5.
15.
J Cameron, N Mahanonda, C Aroney, J Hayes, P McEniery, M Gardner, N Bett.
Outcome five years after percutaneous transluminal coronary angioplasty or coronary
artery bypass grafting for significant narrowing limited to the left anterior descending
coronary artery. Am J Cardiol 1994; 74:544-549.
16.
MJ Semigran, CN Aroney, HC Herrmann, GW Dec, CA Boucher, MA Fifer. Effects of
atrial natriuretic peptide on left ventricular function in hypertension.
Hypertension 1994; 24:271-9.
17.
MA Sankardas, P McEniery, C Aroney, G Holt, J Cameron, P Garrahy, A Dare, N Bett.
Directional coronary atherectomy for lesions of the proximal left anterior descending
artery: Initial clinical results, complications and histopathological findings. Aust NZ J
Med 1995; 25:676-80.
18.
M Lynch, NV Hoffmann, CN Aroney. Thrombolytic treatment and proteinuria.
British Heart Journal. 1995; 74:354-7.
19.
ISIS-4 Collaborative Group. ISIS-4: A randomized factorial trial assessing early oral
captopril, oral mononitrate, and intravenous magnesium sulphate in 58,080 patients with
suspected acute myocardial infarction. Lancet 1995; 345:669-85.
20.
MA Sankardas, PT McEniery, CN Aroney, JHN Bett. Elective implantation of
intracoronary stents without intravascular ultrasound guidance or subsequent warfarin.
Cathet Cardiovasc Diagn. 1996; 36:355-9.
21.
CN Aroney, MB Davison, EG Stafford, MF O’Brien. Internal mammary vein to
coronary artery anastomotic fistula. Cathet Cardiovasc Diagn 1996; 39:407-9.
22.
CK Ponde, CN Aroney, PT McEniery, JHN Bett. Plaque prolapse between the struts of
the intracoronary palmaz-Schatz stent: Report of two cases with a novel treatment of this
unusual problem. Cathet Cardiovasc Diagn. 1997; 40:353-7.
23.
NM Caplice, CN Aroney, JHN Bett, J Cameron, JH Campbell, N Hoffmann, PT
McEniery, MJ West. Growth factors released into the coronary circulation after vascular
injury promotes proliferation of human vascular smooth muscle cells in culture.
J Am Coll Cardiol. 1997; 29:1536-41.
24.
AM Tonkin and CN Aroney. Guidelines for managing patients with unstable angina.
Rating the evidence and rationale for treatment. Med J Aust 1997; 166:644-7.
25.
CN Aroney. Improving the results of coronary angioplasty. Aust NZ J Med 1997;
37:510-4.
26.
CK Ponde, PS Watson, CN Aroney, M Dooris, PJ Garrahy, J Cameron, PT McEniery,
JHN Bett. Multiple stent implantation in single coronary arteries: acute results and sixmonth angiographic follow-up. Cathet Cardiovasc Diagn 1997; 42:158-65.
27.
N Dwiveedi, CN Aroney, R Slaughter. Thrombosis of a mechanical tricuspid valve
prosthesis and of the left subclavian vein: Successful therapy with thrombolysis.
Cath Cardiovasc Diagn 1998; 43:84-6.
28.
PS Watson, CK Ponde, CN Aroney, J Cameron, A Cannon, M Dooris, PJ Garrahy,
PT McEniery, JHN Bett. Angiographic follow-up and clinical experience with the
flexible tantalum Cordis stent. Cathet Cardiovasc Diagn 1998; 43:168-73.
29.
CN Aroney, RN Justo DJ Radford. PTCA in a 30 month old child with embolic long
segment occlusion of the left anterior descending artery. Cathet Cardiovasc Diagn 1998;
44:206-9.
30.
CN Aroney, JHN Bett. Transmyocardial laser revascularisation: Have we trodden this
path before? (Letter) Asia Pacific Heart J 1998; 7:131.
31.
PS Watson, GM Scalia, AJ Galbraith, JHN Bett, CN Aroney. Lack of effect of
coenzyme Q on left ventricular function in patients with congestive heart failure.
Coll Cardiol 1999; 33:1549-52.
J Am
32.
CN Aroney. Unstable angina: calming the troubled waters. Modern Medicine of
Australia. October 1999.
33.
CN Aroney. A new technique to guarantee access to the sidebranch during bifurcational
coronary stenting. J Invas Cardiol 2000; 12:25-28.
34.
J Cameron, C Aroney, J Bett. Left main coronary artery dissection during coronary
angioplasty or angiography treated by stent insertion without requirement for emergency
bypass graft surgery. Aust NZ J Med 2000; 30:726-8.
35.
CN Aroney, AN Boyden, MV Jelinek, P Thompson, AM Tonkin, H White.
Management of unstable angina guidelines – 2000. Med J Aust 2000; 173(supplement):
S65-S88.
36.
CN Aroney, AN Boyden, MV Jelinek, P Thompson, AM Tonkin, H White. Current
guidelines for the management of unstable angina: a new diagnostic and management
paradigm. Intern Med J: 2001; 31:104-11.
37.
CN Aroney, MV Jelinek, AM Tonkin, J Vinen, H White. Management of unstable
angina. Reply. (letter) Med J Aust 2001; 174:423-4.
38.
CN Aroney, P Thompson, AM Tonkin, H White. Management of unstable angina. Reply.
(letter) Med J Aust 2001; 174:424-5.
39.
CN Aroney. Management of the acute coronary syndromes. Australian Prescriber 2001;
24:56-9.
40.
P Aylward, D Hunt, C Aroney, A. Boyden, S. Bunker, I. Cameron, J. Carapetis, G.
Carroll, S. Couzos, P. Fletcher, P. French, D. Hunt, M. Loughhead, J. Parikh.
Reperfusion therapy for acute myocardial infarction. Heart, Lung and Circulation 2001;
10: 99
41.
GG Schwartz, AG Olsson, MD Ezekowitz et al. Effects of atorvastatin on early recurrent
ischemic events in acute coronary syndromes: the MIRACL study: a randomized
controlled trial. JAMA 2001; 285: 1711-8.
42.
M Roffi, DJ Moliterno, B Meier et al. Impact of different platelet glycoprotein IIb/IIIa
receptor inhibitors among diabetic patients undergoing percutaneous coronary
intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial
(TARGET) 1-year follow-up. Circulation 2002; 105: 2730-6.
43.
DJ Moliterno, SJ Yakubov, PM DiBattiste et al. Outcomes at 6 months for the direct
comparison of tirofiban and abciximab during percutaneous coronary revascularisation
with stent placement: the TARGET follow-up study. Lancet 2002; 360: 355-60.
44.
CN Aroney. Media coverage of scientific presentations (letter). Med J Aust. 2002;
177:374-5.
45.
C Aroney, P Thompson. Warfarin and antiplatelet drugs (letter). Australian Prescriber
2002; 25:131.
46.
E Strodl, J Kenardy, C Aroney. Perceived stress as a predictor of the self-reported new
diagnosis of symptomatic CHD in older women. International Journal of Behavioural
Medicine. 2003; 10:205-220.
47.
AW Chan, DJ Moliterno, PB Berger et al. Triple antiplatelet therapy during percutaneous
coronary intervention is associated with improved outcomes including one-year survival:
results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial
(TARGET). J Am Coll Cardiol 2003; 42: 1188-95.
48.
CN Aroney, HL Dunlevie, JHN Bett. Use of an accelerated chest pain assessment
protocol in patients at intermediate risk of adverse cardiac events. Med J Aust 2003;
178:370-5.
49.
C Aroney, W Lapanun, G Scalia, W Parsonage. Transcatheter treatment of Lutembacher
Syndrome. Internal Med J 2003; 33:259-60.
50.
DL Walters, CN Aroney, DJ Radford. Coronary stenting for a muscular bridge in a
patient with hypertrophic obstructive cardiomyopathy. Cardiol Young 2003; 13:377-9.
51.
J Hung, C Aroney, A Boyden, D Hunt, A Tonkin. Aspirin for cardiovascular disease
prevention. Med J Aust 2003: 179:147-52.
52.
J Davies, S Senes, CN Aroney, IT Meredith, L Bernstein. Nineteen year (1990-1998)
review of angioplasty in Australia. Heart, Lung and Circulation 2003; A72-73.
53.
CN Aroney. Myocardial infarction: Improving patient outcomes. Medicine Today - April
2004.
54.
CN Aroney, TH Goh, LA Hourigan, W Dyer. Ventricular septal rupture following nonsurgical septal reduction for hypertrophic cardiomyopathy: Treatment with percutaneous
closure. Cathet Cardiovasc Intervention 2004; 61: 411-4.
55.
JC Tardif, J Gregoire, PL Lallier et al. Effects of the acyl coenzyme A:cholesterol
acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 2004;
110: 3372-7.
56.
I. Scott, J. Chan, C. Aroney, G. Carroll. Local thrombolysis or rapid-transfer for primay
angioplasty for patients presenting with ST segment elevation myocardial infarction to
hospitals without angioplasty facilities. Int Med J 2004; 34: 373-7.
57.
JJ Ferguson, RM Califf, EM Antman et al. Enoxaparin vs unfractionated heparin in
high-risk patients with non-ST-segment elevation acute coronary syndromes managed
with an intended early invasive strategy: primary results of
the SYNERGY randomized trial. JAMA 2004; 292: 45-54.
58.
C Aroney. Heart sounds made easy. (review) Heart Lung and Circulation 2004; 13: 199.
59.
MJ Ray, DL Walters, N Bett, J Cameron, P Wood, C Aroney. Point-of-Care testing
shows clinically relevant variation in the degree of inhibition of platelets by standarddose abciximab therapy during percutaneous coronary intervention. Cathet Cardiovasc
Intervention 2004; 62: 150-4.
60.
PW Serruys, JA Ormiston, G Sianoe et al. Actinomycin-eluting stent
for coronary revascularization: a randomized feasibility and safety study: the ACTION
trial. J AM Coll Cardiol 2004; 44:1363-7.
61.
C Aroney. Cardiac Drug Therapy: Sixth Edition. (review) Heart Lung and Circulation
2004; 13: 430.
62.
MA Blazing, JA de Lemos, HD White et al. Safety and efficacy of enoxaparin vs
unfractionated heparin in patients with non-ST-segment elevation acute coronary
syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 2004;
292:55-64.
63.
DP Chew, RM Allan, CN Aroney, NJ Sheerin. National data elements for the clinical
management of acute coronary syndromes. Med J Aust 2005; 182: S1-S16.
64.
JHN Bett, AM Tonkin, PL Thompson, CN Aroney. Failure of current public educational
campaigns to impact on the initial response of patients with possible heart attack. Int Med
J 2005; 279-82.
65.
MJ Ray, DL Walters, JHN Bett, J Cameron, P Wood, CN Aroney. Platelet-monocyte
aggregates predict troponin rise after percutaneous coronary intervention and are
inhibited by abciximab. Int J Cardiology 2005; 101: 249-55.
66.
C Aroney. Interventional Cardiology Secrets. (review) Heart Lung and Circulation 2005;
14: 124-5.
67.
C Aroney. Stable angina pectoris: Evaluation and treatment. Medicine Today. 2005; 6:
44-53.
68.
S. Trivedi, CN Aroney, DL Walters, JHN Bett. Measurement of myocardial fractional
flow reserve is a cost-effective way to identify coronary artery lesions of indeterminate
severity that warrant revascularisation. Heart Lung and Circulation 2005; 14:239-41.
69.
AP Gunasekara, DL Walters, CN Aroney. Comparison of abciximab with “high dose”
tirofiban in patients undergoing percutaneous coronary intervention. Int J Cardiology
2006; 109:16-20.
70.
CN Aroney, P Aylward, A-M Kelly, E Clune. Guidelines for the management of acute
coronary syndromes 2006. Med J Aust 2006; 184 (Supplement):S1-S30.
71.
MR Hoenig, JA Doust, CN Aroney, IA Scott. Early invasive versus conservative
strategies for unstable angina & non-ST-elevation myocardial infarction in the stent era.
(Cochrane Database of Systematic Reviews 2006. Jul 19;3:CD004815).
72.
P Deedwania, P Barter, R Carmena et al. Reduction of low-density lipoprotein
cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of
the Treating to New Targets study. Lancet 2006; 368: 919-28.
73.
P Aylward, CN Aroney. Guidelines for the management of acute coronary syndromes
2006. Letter. Med J Aust 2006; 185:527.
74.
CN Aroney, P Aylward. Guidelines for the management of acute coronary syndromes
2006. Letter. Med J Aust 2007; 186:101-2.
75.
PJ Barter, M Caulfield, M Erikkson et al. Effects of torcetrapib in patients at high risk for
coronary events. N Eng J Med. 2007; 357:2109-22.
76.
A McCann, DL Walters, CN Aroney. Percutaneous balloon mitral commissurotomy in
indigenous versus non-indigenous Australians. Heart Lung Circ 2008; 17:200-5.
77.
DL Walters, CN Aroney, DP Chew, L Bungey, SG Coverdale, R Allen, D Brieger.
Variations in the application of cardiac care in Australia. Results from a prospective audit
of the treatment of patients presenting with chest pain. Med J Aust 2008; 188:218-23.
78.
CN Aroney, P Aylward, DP Chew, N Huang, A-M Kelly, H White, M Wilson. 2007
addendum to the NHF/CSANZ guidelines for the management of acute coronary
syndromes 2006. Med J Aust 2008; 188:302-3.
79.
I Ranasinghe, D Chew, C Aroney, S Coverdale, R Allen, D Walters, D Brieger.
Differences in treatment and management of indigenous and non-indigenous patients
presenting with chest pain: results of the Heart Protection Partnership (HPP) study.
Heart Lung Circ 2009; 18: 32-7.
80.
E Ivens, C Hamilton-Craig, C Aroney, A Clarke, H Jalali, Dj Burstow. Early and late
perforation by Amplatzer atrial septal defect and patent foramen ovale devices. J Am Soc
Echocardiogr 2009; 22:1067-70.
81.
G Montalescot, SD Wiviott, E Braunwald et al. Prasugrel compared with clopidogrel in
patients undergoing percutaneous coronary intervention for ST-elevation myocardial
infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009;
373: 723-31.
82.
D Brieger, A-M Kelly, C Aroney, P Tideman, SB Freedman, D Chew, M Ilton, G
Carroll, I Jacobs, NP Huang. Acute coronary syndromes: consensus recommendations for
translating knowledge into action. Med J Aust 2009; 191:334-9.
83.
DL Bhatt, AM Lincoff, CM Gibson et al. Intravenous platelet blockade
with cangrelor during PCI. N Eng J Med 2009; 361: 2230-41.
84.
The Expanded Global Registry of Acute Coronary Events (GRACE2) Investigators.
The expanded Global Registry of Acute Coronary Events: baseline characteristics,
management practices, and hospital outcomes of patients with acute coronary syndromes.
Am Heart J 2009 158:193-201.
85.
Dal-OUTCOMES Committees and Investigators. Rationale and design of the dalOUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute
coronary syndrome. Am Heart J 2009 158:896-901.
86.
DL Walters, MJ Ray, P Wood, EJ Perrin, JHN Bett, CN Aroney. High-dose tirofiban
with enoxaparin and inflammatory markers in high-risk percutaneous intervention. Eur J
Clin Invest 2010; 40:139-47.
87.
CN Aroney, PE Hickman, HG Schneider, JR Tate, M Than. Troponin measurement and
the new assays – How low can we go? Med J Aust 2010; 192:245-6.
88.
PE Hickman, JM Potter, CN Aroney, G Koerbin, E Southcott, AHB Wu, MS Roberts.
Cardiac troponin may be released by ischemia alone, without necrosis. Clin Chim Acta
2010; 411:318-23.
89.
D Brieger, C Aroney, D Chew, A-M Kelly, D Walters, Toohey C, Boyden A. Acute
coronary syndromes: consensus recommendations for translating knowledge into action.
Med J Aust 2010; 192:700-1.
90.
J Layland, B Bell, J Latona, D Mullany, G Manaharan, B Thompson, C Aroney, D
Walters. Novel use of a percutaneous aortic valve in stentless bioprosthetic Cryolife
O’Brien valve dysfunction. J Heart Valve Dis 2010; 19:263-4.
91.
C Aroney. The acute coronary syndrome. Cardiology in General Practice 2010; 11:23-5.
92.
MR Hoenig, CN Aroney, IA Scott. Early invasive versus conservative strategies for
unstable angina & non-ST-elevation myocardial infarction in the stent era. Cochrane
Database of Systematic Reviews 2010; Mar 17; 3:CD004815.
93.
DMACS Project Team. Discharge management of acute coronary syndromes project.
National Prescriber Service; Dec 2010.
94.
DP Chew, CN Aroney, PE Aylward, AM Kelly, HD White, PA Tideman, J Waddell, L
Azadi, AJ Wilson, LM Ruta. 2011 Addendum to the National Heart Foundation of
Australia/Cardiac Society of Australia and New Zealand Guidelines for the management
of acute coronary syndromes (ACS) 2006. Heart Lung Circ 2011; 20:487-503.
95.
CN Aroney. A suggested paradigm for coronary risk screening in asymptomatic persons
– assessment of total coronary atheromatous burden. Heart Lung Circ 2012; 21: 449-54.
96.
KK Poon, J Crowhurst, C James, D Campbell, D Roper, J Chan, A Incani, P Tesar, C
Aroney, OC Raffel, DL Walters. Impact of optimising fluoroscopic implant angles on
paravalvular regurgitation in transcatheter aortic valve replacements – utility of three
dimensional rotational angiography. Eurointervention 2012; 8: 538-45.
97.
DL Walters, T Boga, D Burstow, G Scalia, LA Hourigan, CN Aroney. Percutaneous
ASD closure in a large Australian series – short and long term outcomes. Heart Lung Circ
2012; 21: 572-5.
98.
KK Poon, A Clarke, SA Luis, P Wiemers, A Incani, G Scalia, P Tesar, OC Raffel, CN
Aroney, DL Walters. First Australian trans-apical mitral valve-in-valve implant for a
failed bioprosthesis. How to do it. Heart Lung Circ 2012; 21: 737-9.
99.
Incani A, Butler T, Poon K, Savage M, Aroney C, Raffel C, Walters D. Investigating the
relationship between CRUSADE Bleeding Score and bleeding in TAVR patients – The
Prince Charles Registry. Heart Lung Circulation 2012 05 403
100.
P Tricoci, Z Huang, C Held et al. Thrombin-receptor antagonist varoxapar in acute
coronary syndromes (TRACER). New Eng J Med 2012; 366: 20-33.
101.
DA Morrow, E Braunwald, MP Bonaca et al. Vorapaxar in the secondary prevention of
atherothrombotic events. N Eng J Med 2012; 366: 1404-13.
102.
GG Schwartz, AG Olsson, M Abt et al. Effects of dalcetrapib in patients with a recent
acute coronary syndrome. New Eng J Med 2012; 367: 2089-99.
103.
Crowhurst Jam Campbell D, Raffel C, Whitby M, Pathmanthan P, Redmond S, Incani A,
Poon K, James C, Aroney C, Clarke A, Walters DL. Using Dyna CT for the assessment
of iliofemoral arterial calibre, calcification and tortuosity index in patients selected for
trans-catheter aortic valve replacement. Int J Cardiovasc Imaging 2013; 29: 1537-45.
104.
Subban V, Incani A, Clarke A, Aroney C, Scalia G, Crowhurst J, Raffel C, Walters DL.
Conservative management and resolution of a contained rupture of aortic annulus
following trans-catheter valve replacement. JACC Cardiovasc Interv 2013; 6: 33-4.
105.
A Clarke, P Wiemers, KK Poon, CN Aroney, G Scalia, D Burstow, DL Walters, P Tesar.
Early experience in trans-aortic TAVI – The future of surgical TAVI. Heart Lung Circ
2013; 22:265-269.
106.
A Murdoch, J Hunter, A Incani, O Raffel, CN Aroney, D Walters. Percutaneous aortic
balloon valvuloplasty is a safe and effective bridging procedure to transcutaneous aortic
valve replacement. Heart Lung Circulation 2013;
107.
C Aroney. Primary prevention of cardiovascular disease: new guidelines, technologies
and therapies. Med J Aust 2014; 200:146-8.
108.
H Samardhi, DL Walters, C Raffel, S Rateesh, C Harley, D Burstow, P Pohlner, C
Aroney. The long-term outcomes of transcoronary ablation of septal hypertrophy
compared to surgical myectomy in patients with symptomatic hypertrophic obstructive
cardiomyopathy. Cath Cardiovasc Interventions 2014; 83: 270-7.
109.
Subban V, Savage M, Crowhurst J, Poon K, Incani A, Aroney C, Tesar P, Clarke A,
Raffel C, Murdoch D, Platts D, Burstow D, Saireddy R, Bett N, Walters D. Transcatheter vave-in-valve replacement of degenerated bioprosthetic aortic valves. A single
centre Australian experience. Cardiovascular revascularisation medicine 2014; 15:38892.
110. C Aroney. Transcutaneous aortic valve implantation – A call for action. (Lead Editorial)
Heart Lung Circ 2015; 24:216-8.
111.
JA Crowhurst , M Savage,·V Subban,·A Incani,·OC Raffel, K Poon, D Murdoch, R
Saireddy, A Clarke, C Aroney, N Bett, D L Walters. Factors Contributing to Acute
Kidney Injury and the Impact on Mortality in Patients Undergoing Trans-catheter Aortic
Valve Replacement. Heart Lung Circulation 2016; 25: 282-9.
112.
V Subban, D Murdoch, ML Savage, J Crowhurst, R Saireddy, KK Poon, A Incani, N
Bett, DJ Burstow, GM Scalia, A Clarke, OC Raffel, CN Aroney, DL Walters. Outcomes
of transcatheter aortic valve implantation in high surgical risk and inoperable patients
with aortic stenosis: a single Australian Centre experience. Int Med J. 2016; 46: 42-51.
113.
C Aroney, L Cullen. Appropriate and inappropriate use of serum troponin in General
Practice – A Narrative Review. Med J Aust (In Press).
Book Chapters
1.
CN Aroney, JA de Lemos. Management of acute coronary syndromes. Chapter 2 Pp
15-36 in Cardiac Markers (2nd Edition, 2003), Editor AH Wu; Humana Press.
2.
CN Aroney. Management of the NSTE acute coronary syndromes. Chapter 64 Pp 485-95
in Coronary Care Manual (2nd edition, 2010), Editor Peter Thompson; Elsevier Australia.
Abstracts:
1.
CN Aroney, MR Nicholson, JE Shevland. 2-D echocardiographic features of cardiac
compression by mediastinal pancreatic pseudocyst. Aust Soc for Ultrasound in
Medicine, Adelaide, 1984.
2.
CN Aroney, HE Butler, M Staley, MR Nicholson. Hypokalemia in patients receiving
fixed-combination diuretics. Cardiac Soc of Aust and NZ, Adelaide, 1986.
3.
CN Aroney, JHN Bett, J Egerton-Vernan, C Boyle, L Dryberg. The influence of IV
nitroprusside, oral hydrallazine and metoprolol on infarct expansion in acute anterior
transmural myocardial infarction. Asian-Pacific Congress in Cardiology, Auckland,
NZ, 1987.
4.
CN Aroney, JHN Bett, J Whiting, C Boyle. Identification of vegetations with
echocardiography in septicaemic patients. Asian-Pacific Congress in Cardiology,
Auckland, NZ, 1987.
5.
CN Aroney, MA Fifer, CA Boucher. Left ventricular contractile function in mitral
regurgitation: Rheumatic heart disease compared with mitral valve prolapse. Am Fed
Clin Res, Washington, DC, 1988.
6.
MJ Semigran, CN Aroney, HC Herrmann, GW Dec, CA Boucher, MA Fifer. Relative
effects of inferior vena caval occlusion and nitroprusside infusion on left ventricular
loading conditions in man. Am Fed Clin Res, Washington, DC, 1988.
7.
TP Rocco, V Dilsizian, CN Aroney, HW Strauss, R Zusman, CA Boucher. Abnormal left
ventricular volume response predicts exercise performance in hypertension. Am Coll
Cardiol, Atlanta, Georgia, March 1988.
8.
CN Aroney, MJ Semigran, GW Dec, CA Boucher, MA Fifer. Calcium channel
blockade does not improve left ventricular diastolic function in patients with severe heart
failure. Am Heart Assoc, Washington DC, Nov 1988.
9.
CN Aroney, MJ Semigran, GW Dec, CA Boucher, MA Fifer. Negative inotropic effect
of nicardipine in patients with heart failure: Demonstration by left ventricular endsystolic pressure-volume analysis. Am Coll Cardiol, Anaheim, California, March 1989.
10.
MJ Semigran, CN Aroney, GW Dec, HC Herrmann, CA Boucher, MA Fifer. Lack of
inotropic effect of atrial natriuretic factor in humans with heart failure: Demonstration
by left-ventricular end-systolic pressure-volume analysis. Am Coll Cardiol, Anaheim,
California, March 1989.
11.
MJ Semigran, CN Aroney, GW Dec, HC Herrmann, CA Boucher, MA Fifer. Effect of
atrial natriuretic factor on left ventricular diastolic function in humans with heart failure.
Am Coll Cardiol, Anaheim, California, March 1989.
12.
MJ Semigran, MA Fifer, HC Herrmann, CN Aroney, GW Dec. Coronary artery disease
predicts early mortality in patients with severe heart failure treated with enoximone. Am
Fed Clin Res, 1989.
13.
MJ Semigran, CN Aroney, GW Dec, HC Herrmann, CA Boucher, MA Fifer. Atrial
natriuretic factor is a vasodilator with no direct myocardial effect. Am Coll Cardiol,
New Orleans, Louisiana, March 1990.
14.
M Masterson, J Hayes, V Singh, R Pascoe, M Davison, C Aroney, A Murphy.
Electrocardiographic analysis: Man versus machine. CSANZ, Hobart, May 1990.
15.
M Masterson, V Singh, J Hayes, R Pascoe, C Aroney, A Murphy. Automated ECG
analysis: Clinical comparison of three interpretive devices. Cardiac Soc of Aust and
NZ, Hobart, May 1990.
16.
CN Aroney, DJ Burstow. Percutaneous mitral valvuloplasty: Age predicts response to
dilatation. Cardiac Soc of Aust and NZ, Perth, August 1991.
17.
C Aroney, N Bett, J Cameron, P Garraghy, G Holt, K Hossack, A Murphy, J O'Keefe,
Q'ld PTCA Group. Relationships between the characteristics of lesions, peak inflation
pressure and angiographic success or local complications of coronary angioplasty.
Cardiac Soc of Aust and NZ, Perth, August 1991.
18.
KT McKenna, PT McEniery, CN Aroney, JHN Bett, J Cameron, G Holt, AL Murphy, F
Maas. Early results and quality of life after percutaneous transluminal coronary
angioplasty. Cardiac Soc of Aust and NZ, Perth, August 1991.
19.
LM Carey, J Cameron, CN Aroney, JHN Bett, PJ Garrahy, GW Holt, N Mahanonda, PT
McEniery. Experience with the Gianturco-Roubin stent for abrupt closure complicating
percutaneous transluminal coronary angioplasty. Cardiac Soc of Aust and NZ,
Melbourne, August 1992.
20.
N Mahanonda, J Cameron, C Aroney, M Gardner, JHN Bett. A comparison of outcome
after angioplasty or surgery for lesions of the left anterior descending coronary artery.
Cardiac Soc of Aust and NZ, Melbourne, August 1992.
21.
MJ Semigran, CN Aroney, GW Dec, MA Fifer. Abnormalities in diastolic function
progress over time in cardiac transplant recipients. Am Heart Assoc, New Orleans,
Louisiana, 1992.
22.
J Cameron, N Mahanonda, C Aroney, J Hayes, P McEniery, M Gardner, JHN Bett.
Comparison of outcome of PTCA and coronary surgery for lesions of the left anterior
descending coronary artery. Am College of Cardiology, Anaheim, California, 1993.
23.
DB Cross, GM Scalia, CN Aroney, JJ Atherton, JHN Bett, JT Rivers, PJO Stride, GW
Holt. Antianginal effects of captopril in hypertensive patients. Am College of
Cardiology, Anaheim, California, 1993.
24.
J Bou-Samra, DJ Burstow, RD Pascoe, CN Aroney. Percutaneous mitral valvuloplasty:
Predictors of response to dilatation. Cardiac Soc of Aust and NZ, Christchurch, August,
1993.
25.
DB Cross, GM Scalia, CN Aroney, JJ Atherton, JHN Bett, JT Rivers, PJO Stride, JA
Karrasch, GW Holt. Antianginal effects of captopril in hypertensive patients. Cardiac
Soc of Aust and NZ, Christchurch, August, 1993.
26.
J Cameron, N Mahanonda, C Aroney, J Hayes, P McEniery, M Gardner, N Bett.
Comparison of quality of life assessment post PTCA and CABG for lesions of the left
anterior descending artery. Cardiac Soc of Aust and NZ, Christchurch, August, 1993.
27.
JE Donnelly, DJ Burstow, CN Aroney, JHN Bett, J Cameron, PJ Garrahy, BR Harkness,
GW Holt, AS Mullasari, PT McEniery. Cardiac Soc of Aust and NZ, Adelaide, 1994.
28.
NM Caplice, C Aroney, JHN Bett, J Cameron, P McEniery, MJ West. PDGF release
into the coronary circulation following coronary angioplasty in humans. Cardiac Soc of
Aust and NZ, Adelaide, 1994.
29.
AS Mullasari, CN Aroney, J Cameron, P Garrahy, G Holt, P McEniery, JHN Bett.
Angiographic and procedural predictors of dissection after percutaneous coronary
angioplasty. Cardiac Soc of Aust and NZ, Adelaide, 1994.
30.
JHN Bett, J Cameron, N Mahanonda, CN Aroney, JR Hayes, MAH Gardner, P
McEniery. Survival and symtom status after angioplasty or surgery for lesions of the left
anterior descending coronary artery. European Congress of Cardiology, Berlin, 1994.
31.
M Lynch, NV Hoffmann, CN Aroney. Thrombolytic therapy and proteinuria.
American Heart Association, Dallas, 1994.
32.
AS Mullasari, PT McEniery, CN Aroney, J Cameron, JHN Bett. Elective intracoronary
stent implantation without ultrasound guidance or subsequent warfarin. Soc for Cardiac
Angiography and Interventions, Orlando, 1995.
33.
N Mahanonda, J Cameron, CN Aroney, JR Hayes, MAH Gardner, P McEniery, JHN
Bett. Outcome five years after angioplasty or surgery for lesions of the left anterior
descending artery. Journal of Heart Failure. 1995; 2:1109.
34.
Aroney CN. Mitral balloon valvotomy is effective in the elderly. Cardiac Soc of Aust
and NZ, Canberra, 1995.
35.
Caplice NM, Aroney CN, Bett JHN, Hoffmann N, West MJ. PDGF release into the
coronary circulation following coronary angioplasty in humans.
(Winner of the Ralph Reader Prize). Cardiac Soc of Aust and NZ, Canberra, 1995.
36.
Higgins HC, McKenna KT, McEniery PT, Aroney CN, Cameron J, Garrahy P, Dooris M,
Bett JHN. Return to work after percutaneous transluminal coronary angioplasty
(PTCA): Preliminary Results. Cardiac Soc of Aust and NZ, Brisbane, 1996.
37.
Tooth L, McKenna K, McEniery P, Aroney C, Cameron J, Hossack K, Holt G, Bett JHN.
Educational and demographic factors predicting improved cardiac and risk factor
knowledge after percutaneous transluminal coronary angioplasty (PTCA). Cardiac Soc of
Aust and NZ, Brisbane, 1996.
38.
Aroney CN. Improving the results of coronary angioplasty. The heart and blood
vessels in health and disease. Lindeman Island. August 7-9, 1996.
39.
GMA Scalia, PS Watson, AJ Galbraith, JHN Bett, CN Aroney. Study of CoEnzyme Q
randomized for the treatment of congestive heart failure (SCORCH). Cardiac Soc of
Aust and NZ, Hobart, 1997.
40.
GR Wright-Smith, JHN Bett, P Carroll, P Naidoo, CN Aroney. Value of a bedside assay
of Troponin T in patients with chest pain and a normal ECG. Cardiac Soc of Aust and
NZ, Hobart, 1997.
41.
C Chotinaiwattarakul, AD Cannon, CN Aroney, PT McEniery, PJ Garrahy, M Dooris, J
Cameron, JHN Bett. Early experience with the second generation Gianturco-Roubin
stent. Cardiac Soc of Aust and NZ, Hobart, 1997.
42.
Aroney C, Burns C, Love K. Measures of quality and effectiveness in cardiac care.
IXth Casmix Conference in Australia. Brisbane. September 7-10, 1997.
43.
Aroney CN, Watson PS, Scalia GM, Galbraith AJ, Bett JHN. Study of coenzyme Q
randomized for the treatment of congestive heart failure (SCORCH). Am Heart Assoc,
Orlando, Florida, USA, November, 1997.
44.
Payne J, Hall G, Capra S, Aroney C, Atkinson K, Hourigan A. Changing food patterns
in patients with heart disease - empowering as well as enlightening. Australian Cardiac
Rehabilitation Association Conference. Perth, August 1998,
45.
Cleary S Adlam L, Mason C, Abbott E, Winkler J, Aroney C, Cameron J, McEniery P,
Bett JHN. Examination of groin complications of transluminal coronary angioplasty
patients treated with low molecular weight heparin. Cardiac Soc of Australia and NZ,
Perth, 1998.
46.
Higgins HC, McKenna KT, McEniery PT, Aroney CN, Cameron J, Dooris M, Garrahy P,
Holt G, Bett JHN. Cardiac rehabilitation outcomes following intracoronary stenting
and/or PTCA. Cardiac Soc of Australia and NZ, Perth, 1998.
47.
Payne J, Hall G, Capra S, Aroney C, Atkinson K, Hourigan A. Changing food patterns
in patients with heart disease - empowering as well as enlightening. Aust Cardiac
Rehabititation Conference. Perth, August 1998.
48.
Walters D, Radford DJ, Aroney CN,. Myocardial bridging in hypertrophic
cardiomyopathy: In-stent restenosis following coronary stenting. Royal Australasian
College of Physicians, Perth, May 1999.
49.
Payne J, Aroney C. International Health Outcomes Conference, Canberra, July 1999.
50.
Aroney CN, Bett JHN. Platelet inhibition with abciximab therapy - Preliminary results
using a rapid platelet function assay. Cardiac Soc of Australia and NZ, Wellington,
August 1999.
51.
Aroney CN, Tesar PT, Love K, Bett JHN. Comparison of functional health status before
and after cardiac interventions in the Australia and the USA. Cardiac Soc of Australia
and NZ, Wellington, August 1999.
52.
Payne J, Aroney C. Pacific Partners in Nutrition Conference. Auckland, September 1999.
53.
Aroney CN. Warfarin therapy need not be interrupted for coronary interventions using
radial artery access. Cardiac Soc of Australia and NZ, Melbourne, August 2000.
54.
Riha A, Potter J, Slaughter R, Aroney C. Troponin in Pulmonary Embolism Study.
Cardiac Soc of Australia and NZ, Melbourne, August 2000.
55.
Scalia G, Lange A, Burstow D, Aroney C. 3D echocardiography in ASD closure. Cardiac
Soc of Australia and NZ, Melbourne, August 2000.
56.
Scalia G, Lange A, Polka P, Donnelly J, Burstow D, Aroney C. Clinical utility of 3D
echocardiography in the assessment of atrial septal defect anatomy for Amplatzer device
closure. XXII Congress of the European Soc of Cardiology, Amsterdam, August, 2000.
57.
Payne J, Hall G, Capra S, Aroney C, Atkinson K, Hourigan A. Stages of change and
health locus of control in dietary behaviour change. Sixth International Congress of
Behavioural Medicine, Brisbane, November, 2000.
58.
Strodl E, Kenardy J, Aroney C. Chest pain in elderly women. International Conference
for Behavioural Medicine, Brisbane, 2000.
59.
Aroney CN, Dunlevie H, Bett JHN. Accelerated assessment of chest pain in intermediate
risk patients: Reclassification using the new guidelines. Cardiac Soc of Australia and NZ,
Auckland, August 2001.
60.
Harris AM, Burstow DJ, Aroney CN. Transcoronary ablation of septal hypertrophy –
Preliminary acute results. Cardiac Soc of Australia and NZ, Auckland, August 2001.
61.
Trivedi S, Aroney CN. Same day discharge percutaneous coronary intervention. Why
delay? Cardiac Soc of Australia and NZ, Auckland, August 2001.
62.
Strodl E, Kenardy J, Aroney C. Psychological factors and angina. Australian Cardiac
Rehabilitation Annual Scientific Meeting, Noosa, September 2001.
63.
Bett JHN, Aroney C, Dunlevie H. Guidelines for management of patients presenting with
chest pain and features of intermediate risk. World Congress of Cardiology, Sydney, May
2002.
64.
Trivedi S, Aroney CN. Correlation between coronary angiographic anatomy and troponin
I levels in patients with acute chest pain. World Congress of Cardiology, Sydney, May
2002.
65.
Trivedi S, Aroney CN, Walters DL, Bett N. Measurement of myocardial fractional flow
reserve using the Radi wire identifies coronary lesions warranting revascularistion. World
Congress of Cardiology, Sydney, May 2002.
66.
Ray MJ, Bett JHN, McEniery PT, Walters DL, Aroney CN. Point of care monitoring of
platelet function after abciximab therapy is poorly correlated with flow-cytometric
measurements of platelet activation. World Congress of Cardiology, Sydney, May 2002.
67.
Davies J, Senes S, Aroney CN, Meredith IT, Bernstein L. Nineteen year (1980-1998)
review of coronary angioplasty in Australia. World Congress of Cardiology, Sydney,
May 2002.
68.
Strodl E, Colquhoun D, Aroney C, Kennardy J. Autonomic nervous system arousal and
the frequency of angina attacks. European Atherosclerosis Society Congress, Salzburg,
2002.
69.
Strodl E, Aroney C, Colquhoun D, Kenardy J. Heart rate variability and the frequency of
angina. European Atherosclerosis Society Congress, Salzburg, July 2002.
70.
Strodl E, Kenardy J, Aroney C. Prediction of the new diagnosis of coronary heart
disease in older women using psychosocial predictors. Stress and Anxiety Research
(STAR) International Conference, Melbourne July 2002.
71.
Strodl E, Kenardy J, Aroney C. Psychological factors and angina pectoris: The influence
of moderators. International Congress of Applied Psychology, Singapore, July 2002
72.
Strodl E, Kenardy J, Aroney C. Cognitive and Behaviour Therapy and cardiac
rehabilitation. Australian Association for Cognitive and Behaviour Therapy - National
Conference, Brisbane, July 2002
73.
Ray M, Walters D, Bett N, McEniery P, Cameron J, Wood P, Aroney C. Point of care
testing shows clinically relevant variation in the degree of inhibition of platelets by
standard dose abciximab therapy during percutaneous coronary intervention. XIVth
Congress of the International Society on Thrombosis and Haemostasis, Edinburgh, July
2003
74.
Bett JHN, Tonkin AM, Thompson PJ, Aroney CN. Earlier treatment of heart attacks
despite lack of effect of education campaigns on patient delay. Cardiac Soc of Australia
and NZ, Adelaide, August 2003.
75.
Bett JHN, Aroney CN, Dunlevie H. Use of a structured protocol for assessing patients
with chest pain and intermediate risk of adverse events. Cardiac Soc of Australia and NZ,
Adelaide, August 2003.
76.
Walters DL, Aroney CN, Rahman, S, Hourigan LA, Scalia GS, Burstow DJ. Initial
experience with intracardiac echocardiography in the cardiac interventional laboratory.
Cardiac Soc of Australia and NZ, Adelaide, August 2003.
77.
Walters DL, Ray MJ, Bett JHN, Wood P, Aroney CN. High dose Tirofiban with
enoxaparin or unfractionated heparin in patients undergoing coronary stent placement
reduces CD40 Ligand expression. Cardiac Soc of Australia and NZ, Brisbane, August
2004.
78.
Walters DL, Aroney CN, Allan R, Breiger D, Brunker S, Coverdale S, Hare D,
Rosenhain S. Quality of care of patients hospitalised with acute coronary syndromes.
Cardiac Soc of Australia and NZ, Brisbane, August 2004.
79.
Chen VHT, Fung PR, Carle AD, Nellet, Licastro R, Aroney CN. Cardiac risk factors and
quality of life at 12 months following traditional cardiac rehabilitation – a prospective
cohort controlled study. Cardiac Soc of Australia and NZ, Brisbane, August 2004.
80..
Gunasekara AP, Walters DL, Aroney CN. Comparison of abciximab with “high-dose”
tirofiban in patients undergoing percutaneous coronary intervention. Cardiac Soc of
Australia and NZ, Brisbane, August 2004.
81.
Bett JHN, Tonkin AM, Thompson PL, Aroney CN. Experience is not always a good
teacher: Patients known to have heart disease may delay seeking health for symptoms of
possible heart attack. Cardiac Soc of Australia and NZ, Brisbane, August 2004.
82.
Walters DL, Aroney CN, Bett JHN, Ray MJ, Wood P. A comparison of enoxaparin and
unfractionated heparin in combination with tirofiban during percutaneous coronary
intervention: effects on inhibition of coagulation. Cardiac Soc of Australia and NZ, Perth,
August 2005.
83.
Hourigan L, Aroney CN, Walters DL. Percutaneous septal occluder devices: A single
centre experience of 133 devices. Cardiac Soc of Australia and NZ, Perth, August 2005.
84.
Aroney CN. Metabolic syndrome, diabetes and the acute coronary syndrome. Asia
Pacific Interventional Advances Conference. Newcastle, Nov-Dec 2005.
85.
McCann A, Aroney C, Walters D. Percutaneous balloon mitral commissurotomy in
indigenous vs non-indigenous Australians in Queensland 1990-2006. Cardiac Soc of
Australia and NZ, Canberra, Aug 2006.
86.
McCann A, Walters D, Aroney C. Percutaneous closure of ventricular septal defects
using the Amplatzer VSD Occluder device. Cardiac Soc of Australia and NZ, Canberra,
Aug 2006.
87.
Walters DL, Ray ML, McCann A, Aroney CN. High bolus tirofiban achieves superior
platelet inhibition to abciximab in patients undergoing coronary stenting. Cardiac Soc of
Australia and NZ, Canberra, Aug 2006.
88.
O’Dwyer K, Walters D, Parsonage W, Yadav R, Roberts C, Kamp M, Aroney C.
Implementation of standardized suite of chest pain and acute coronary syndrome
protocols and pathways. Heart Foundation Conference, Brisbane, May 2008.
89.
Bissessor N, Jayasinghe R, Hourigan L, Scalia G, Burstow D, Aroney C, Walters D.
Percuatneous septal occlude devices for patent foramen ovale. Cardiac Soc of Australia
and NZ, Aug 2008.
90.
Hamilton-Craig C, Ivens EL, Boga T, Aroney C, Walters DL, Burstow DJ. Early and late
cardiac perforation by Amplatzer ASD and PFO devices. Cardiac Soc of Australia and
NZ, Sydney, Aug 2009.
91.
Aroney C, Devlin G, Duffy S, Laborde JC, Manoharan G, Meredith I, Muller D,
Ormiston J, Pasupati S, Walters DL, Walton A. Echocardiographic outcomes at 30 days
following percutaneous aortic valve replacement (PAVR) with Corevalve revalving in
Australia and New Zealand. Cardiac Soc of Australia and NZ, Sydney, Aug 2009.
92.
Aroney C, Devlin G, Duffy S, Laborde JC, Manoharan G, Meredith I, Muller D,
Ormiston J, Pasupati S, Walters DL, Walton A. Percutaneous aortic valve replacement
(PAVR) with Corevalve revalving in Australia and New Zealand – Initial experience.
Cardiac Soc of Australia and NZ, Sydney, Aug 2009.
93.
Clark RA, Wilkinson D, Coffee N, Eckert K, Astles P, Milligan M, Pearce G, Stewart S,
van Gaans V, Turner D, Coombe D, Aroney C, Chew D, Grantham H, Macdonald P,
MacIsaac A, Thompson P, Walsh W, Tonkin A. Mapping services to support a patient’s
journey through evidence based care pathways after a cardiac event. Cardiac Soc of
Australia and NZ, Sydney, Aug 2009.
94.
Aroney C. Budgetary constraints and patient care. Challenges in Cardiology. Brisbane,
April 2010.
95.
Aroney C. Troponin: How low can we go? CSANZ Scientific meeting: AACB
Symposium. Adelaide, August 2010.
96.
Crowhurst J, Aroney C, Walters D. The use of perioperative C arm CT for the accurate
placement of percutaneous aortic valves. Cardiac Soc of Australia and NZ, Adelaide,
Aug 2010.
97.
Kelly N, Walters D, Scalia G, Aroney C, Burstow D. Indexed left atrial volume improves
following percutaneous aortic valve replacement with Corevalve bioprosthesis. Cardiac
Soc of Australia and NZ, Adelaide, Aug 2010.
98.
Nowakowski K, Gleeson S, Mullany D, Gough C, Aroney C, Walters D. Patient selection
for percutaneous aortic valve replacement. Cardiac Soc of Australia and NZ, Adelaide,
Aug 2010.
99.
Samardhi H, Rateesh S, Syed F, Harley C, Aroney C, Walters D. An experience of
transcoronary ablation of septal hypertrophy in hypertrophic cardiomyopathy. Cardiac
Soc of Australia and NZ, Adelaide, Aug 2010.
100.
Samardhi H, Rateesh S, Syed F, Harley C, Aroney C, Walters D. Comparison of
transcoronary ablation of septal hypertrophy to surgical myectomy in hypertrophic
cardiomyopathy. Cardiac Soc of Australia and NZ, Perth, Aug 2011.
101.
Incani A, Poon K, Aroney C, Walters D. Major vascular complications and bleeding
during transfemoral aortic valve replacement. Cardiac Soc of Australia and NZ, Perth,
Aug 2011.
102.
Crowhurst J, Campbell D, Robinson B, Poon K, Aroney C, Walters D. Aortic valve guide
– automatic valve annulus profiling for TAVI. First Australian Experience. Cardiac Soc
of Australia and NZ, Perth, Aug 2011.
103.
Crowhurst J, Campbell D, Robinson B, Poon K, Aroney C, Walters D. Accurate
assessment of the femoro-iliac arteries for TAVI using the on table Dyna CT. Cardiac
Soc of Australia and NZ, Perth, Aug 2011.
104.
Incani A, Poon K, Aroney C, Walters D. Transcatheter aortic valve-in-valve
implantations for failed bioprosthetic heart valves at the Price Charles Hospital. Cardiac
Soc of Australia and NZ, Perth, Aug 2011.
105.
Crowhurst J, Incani A, Poon K, Shaffe R, O’Keefe K, Aroney C, Walters D. Contrast use
and acute kidney injury – transfemoral vs transapical approach TAVR: The Prince
Charles Hospital registry data. Cardiac Soc of Australia and NZ, Brisbane, Aug 2012.
106.
Incani A, Butler T, Poon K, Savage M, Aroney C, Raffel C, Walters D. Investigating the
relationship between Crusade Bleeding Score and bleeding in TAVR patients – The
Prince Charles Hospital Registry. Cardiac Soc of Australia and NZ, Brisbane, Aug 2012.
107.
Incani A, Crowhurst J, Poon K, Savage M, Aroney C, Raffel C, Walters D. The clinical
utility of Dyna CT and aortic valve guide software in TAVR – The Prince Charles
Registry. Cardiac Soc of Australia and NZ, Brisbane, Aug 2012.
108.
D Muller, C Aroney, P Jansz, J Passage, D Walters, E Yamen. Six month outcomes of an
initial cohort of patients treated in the Australia and New Zealand Mitraclip Registry. Am
Coll Cardiology 2013.
Reviewer
Heart Disease: A textbook of Cardiovascular Medicine. Braunwald. Eighth Edition 2008.
(International reviewer)
Circulation.
Catheter and Cardiovascular Intervention.
Journal of American College of Cardiology.
European Heart Journal.
Heart.
European Journal of Clinical Investigation.
Medical Journal of Australia.
Heart Lung and Circulation.
Internal Medicine Journal.
International Journal of Cardiology.
Invited Lectures:
1991: Invited lecture tour of Fiji:
"Update in Cardiology"
"Heart Failure: assessment and management"
"Mitral valve disease: new methods in treatment"
1992: Invited Speaker on "After the Infarct", at 1st Annual Heart Week Symposium of the
NHF, May 1993.
1995: Invited Speaker on "Interventional Cardiology in the Elderly", at the Annual Scientific
Meeting of the Australian Society for Geriatrics, June 1995.
1997: Invited Speaker on “Percutaneous Mitral Valvotomy - Treatment of choice for mitral
stenosis?” Cardiac Society of Aust and NZ, Hobart, 1997.
1997: Invited Speaker on “Management of patients with previous coronary artery bypass
surgery” Royal Australasian College of Physicians,
Qld Branch, Noosa,
October, 1997.
1998: Invited Speaker on “Coronary artery bypass surgery will be obsolete by the year 2000”
Cardiac Society of Aust and NZ, Perth, 1998.
1999: Invited Speaker on “Treatment of Bifurcation Lesions - Coronary intervention at the
crossroads” Cardiac Society of Aust and NZ, Wellington, NZ, August, 1999.
2000: Invited Speaker and Live Case Proceduralist, Great Wall Congress of Cardiology,
Beijng, China
2000: Invited Speaker – Current Concepts Lecturer on “Cardiac troponins – Their role in
clinical
cardiology” Australian Association of Clinical Biochemistry. June 2000 (Sydney,
Melbourne and Brisbane lectures)
2000: Invited Speaker on “Invasive management of the acute coronary syndrome” at the
2000 RACQ Annual Scientific Meeting, Coolum, 2000.
2000: Invited speaker on “Outpatient Coronary Interventions” at the Millenium Intervention
Conference, Melbourne, 2000.
2001: Invited Speaker on “The new Australian Guidelines for the Management of Unstable
Angina” at Contemporary Issues in Cardiology, Brisbane, January, 2001.
2001: Invited Speaker on “The diagnosis and management of the acute coronary syndromes” at
Annual Cardiology Pfizer Cardiology Symposium, Surfers Paradise, January, 001.
2001: Invited Speaker on “Innovations in Interventional Cardiology” at Challenges in
Cardiology Brisbane, April 2001.
2001: Invited Speaker on “The new chest pain evaluation strategy” at Qld Clinical Weekend,
21- 22nd July 2001.
2002: Invited Speaker on “Transcoronary ablation of Septal Hypertrophy” at the Interventional
Cardiovascular Symposium, World Congress of Cardiology, Sydney, May 2002.
2002: Invited Speaker on “Management of the acute coronary syndromes”, at the Cardiology
Symposium 2002, Bristol Myers Squib, Surfers Paradise.
2003: Invited Speaker on “Drug eluting stents” at Challenges in Cardiology, Brisbane, June 3.
2003: Invited speaker on “Clinical Practice Guidelines: Writing and Implementation”;
“Drug Eluting Stents”; “Acute coronary syndrome: diagnosis and management”
and “A-Z Study” at the Cardiac Society of Aust NZ, Adelaide, Adelaide, August, 2003.
2004: Invited Speaker on “Management of the acute coronary syndrome” at the Quality and
Innovation in Cardiac Care 2004, Princess Alexandra Hospital, Brisbane.
2004: Invited Speaker on “The Acute Coronary Syndrome”, “Advances in Non-Coronary
Percutanous Interventions” at Tasmanian Cardiology Symposium Nov, 2004.
2004: Invited Speaker on “Fish Oils – Music for your heart”, at Controversies in Cardiology,
Surfers Paradise May, 2004.
2005: Invited Speaker on “Metabolic Syndrome and Cardiovascular Disease”, at
Controversies in Cardiology, Surfers Paradise May, 2005.
2005: Invited Speaker on “Metabolic Syndrome, Diabetes and the Acute Coronary Syndome”,
at the Asia Pacific Interventional Advances Conference, Newcastle December 2005.
2006: Invited Speaker on “ACS Guidelines 2006” at CSANZ Annual Scientific Meeting,
2006:
2007:
2007:
2007:
2007:
2008:
2008:
2009:
2009:
2009:
2011:
2012:
2012:
2012:
Canberra
Invited Speaker on “Diagnostic Cutoffs for Troponin: The Clinicians Perspective” at
Cardiac Society of Aust NZ, Canberra 2006
Keynote Speaker on “Troponin in Clinical Cardiology” at Challenges in Cardiology,
Heart Foundation/CSANZ meeting, Brisbane
Invited Speaker at CSANZ Annual Scientific Meeting, Christchurch NZ, on
Debate: Coronary artery disease should be revascularised
Platelelet inhibitor therapy in interventional cardiology
Invited Speaker at Qld RACP meeting, Noosa Qld, on “Medicine or Intervention for
Coronary Artery Disease”.
Invited Speaker: The Neil Gollan Lecture, Launceston General Hospital, Launceston,
Tasmania.
Invited Speaker: Challenges in Cardiology (Heart Foundation), Brisbane, on “Have we
lost the battle against cardiovascular disease”.
Debate: CT Angiography For and Against. Qld CSANZ Annual Seminar, July 2008
Masterclass in Cardiology: Perth, Western Australia.
Redefining risk in the acute coronary syndrome. ANZET Symposium, Sydney, August
Troponin from the cardiologists viewpoint. AACB 47th Annual Scientific Conference,
Brisbane 2009.
Masterclass in Cardiology; Sydney Australia
Invited Australian representative, International ACS Forum, Eur Soc Cardiology,
Munich.
Invited Speaker at CSANZ Annual Scientific Meeting, Brisbane, Aug 2012
Guidelines for optimal antiplatelet therapy in ACS and PCI. Which drug, when and for
how long.
PCI is the best treatment for STEMI.
Invited Live Case Proceduralist, ANZET Annual Scientific meeting, 2012.
ACCEL Interviews: (American College of Cardiology Extended Learning - audiotape series)
September 1997:
Balloon valvuloplasty – C Aroney.
December 1998:
Coronary bypass surgery will be obsolete in the new millennium – C
Aroney.
Research in Progress:
REDUCE-IT Study
Investigator/collaborator
ODYSSEY Study
Investigator/collaborator.
Pfizer Studies on PCSK9 inhibitors
Previous Mulitcentre Studies
PEGASUS Trial
MIRACL Trial
Investigator/collaborator.
TARGET Study
A-Plus study
TNT study
A-Z study
Action study
OnTarget study
TRANSCEND
ASSENT -4 study
OASIS-5 study.
SYNERGY trial.
ILLUMINATE trial
TRITON-TIMI 38
CHAMPION trial
TRACER study
TRA2P-TIMI 50
VISTA 16 trial
Dal-Acute study
Dal-Outcomes study
REDUCE-IT Study
PEGASUS Study
ODYSSEY Study
MODIFY Study
GLAGOV Study
Investigator/collaborator.
Investigator/collaborator.
Investigator/collaborator.
Investigator/collaborator.
Investigator/collaborator.
Investigator/collaborator.
Investigator/collaborator.
Investigator/collaborator.
Investigator/collaborator.
Investigator/collaborator.
Investigator/collaborator.
Investigator/collaborator.
Investigator/collaborator.
Investigator/collaborator
Investigator/collaborator.
Investigator/collaborator.
Investigator/collaborator.
Investigator/collaborator.
Investigator/collaborator.
Investigator/collaborator.
Investigator/collaborator.
Investigator/collaborator.
Investigator/collaborator.
Registries
RUBY registry
Balloon guidewire protection in ACS
Endeavour registry
Drug eluting Stent registry
CYPHANZ registry
Cypher stent registry
GRACE2 registry
ACS registry
Medtronic Aust/NZ Corevalve registry
REPRISE registry
Lotus TAVI implants
Special Interests:
Interventional Cardiology:
Coronary angioplasty and stent implantation.
Percutaneous mitral balloon valvuloplasty.
Percutaneous aortic valve implantation.
Mitral Clip implantation.
Percutaneous ASD & PFO closure.
Trans-Coronary Septal Ablation for Hypertrophic Cardiomyopathy.
Acute coronary syndromes: Guidelines author.
Clinical Practice Guidelines in Cardiology.
Assessment of left ventricular systolic and diastolic function.
Screening for coronary artery disease.
Quality Activities
1986: Biostatistics Course - 10 week course at QUT
1991-2004: Convenor of weekly Cardiology Journal Club at The Prince Charles Hospital
for medical staff and students.
Regular nursing educational rounds in CCU at PCH
1991: NHMRC Clinical Trials Course - Clinical Trials Centre, Sydney.
1991-2003: Tutor/Trial Examiner for FRACP Advanced Trainees.
1991-2003: Convenor of Cardiac Journal Club - PCH
1991-2002: Convenor of CCU Weekly Clinical Conference - PCH
1995: Health Outcomes and the SF36 - Seminar, Canberra.
1996: Course Director and Convenor of Trans-Australian Interventional Coronary
Symposium. Brisbane Sheraton Hotel - August 1996.
1996: Workshop on teaching clinical skills in the new Graduate Medical Course.
16/10/96 - Mater Hospital.
1996-9: Health outcomes study following PTCA and CABG, Prince Charles Hospital.
1998-2004: Steering committee member and chairman (2000): Current and future
management of unstable coronary syndromes symposia.
1999-2004: National steering committee member, Aggrastat in unstable angina.
Course Director and Convenor of Trans-Radial Intervention Workshop.
November, 1999, Prince Charles Hospital.
–2001: Cardiac Health Outcomes Reference Group (associated with Brisbane North Division
of General Practice) – development of guidelines for risk reduction post MI.
1999: Member steering committee and principal author for developing Australian
guidelines for the management of unstable angina (sponsored by NHF and CSANZ).
: National steering committee, Abciximab in clinical practice.
2003:
Steering committee chairman, Controversies in Cardiology, Inaugural Meeting,
Gold Coast June 2003.
2001-3: PhD Supervisor for Esben Strodl, University of Qld.
2003: Review of National Heart Foundation and Prince Charles Hospital Foundation
Cardiovascular Research Centre (with S Harrap, R Cross, D Kavanagh, T Marwick, D Radford,
A Tonkin)
2004: Convenor, Annual Scientific Meeting, CSANZ, Brisbane 2004.
2004-8 Steering Committee Member, Sanofi Vascular Event, Sydney .
2004-8 Steering Committee Chairman, Controversies in Cardiology, Surfers Paradise.
2001-8 Chairman of morbidity and mortality audit, Holy Spirit Northside Hospital.
Teaching
1985 Co-ordinator of teaching sessions in cardiology for FRACP trainees at RBH.
1986 Cardiology tutor for FRACP and psychiatry trainees, at PCH.
1987-9 Cardiology tutor for Harvard University medical students, at Massachusetts General
Hospital. Coronary care teaching sessions for residents and interns in Phillips House
CCU, Massachusetts General Hospital.
1989 Co-ordinator of formal teaching sessions in cardiology for FRACP trainees at the Mater
Hospital.
Co-ordinator cardiac journal club at PCH.
Lectures at cardiac conference PCH:
assessment of left ventricular systolic function
assessment of left ventricular diastolic function
percutaneous balloon valvuloplasty in adults
Lectures at grand rounds Mater Hospital:
management of coronary artery disease
assessment of left ventricular function
1990 Co-ordinator weekly formal teaching sessions in cardiology for FRACP trainees at
Royal Brisbane Hospital.
1995: Lectures at cardiac conference PCH: balloon valvotomy - an update.
1996 Lectures at cardiac conference PCH: problems in interventional cardiology.
1997 Lectures at cardiac conference PCH: the open artery hypothesis.
Lecture at Grand Rounds PCH: Mitral Balloon Valvotomy.
2002: Lecture at Grand Rounds PCH: Management of unstable angina.
2010: Lecture at Grand Rounds PCH: Assessing the asymptomatic patient for coronary artery
disease.
1991-2002:
Co-ordinator weekly educational CCU rounds at The Prince Charles Hospital
for medical staff and students.
Regular lecture on "Interventional Cardiology" to Coronary Care Module at PCH.
Regular lecture on "Guidelines for managing NTEACS" for FRACP trainees at RACP Herston
Tutorials for Qld University medical students
1991-7: Clinical skills sessions in cardiology for Year 4-5 students
2 hour tutorial sessions.
Clinical attachments for Year 6 students
1997:
Clinical Immersion for Year 1 student GMC October 1997
1998:
Clinical tutor for Year 2 Graduate Medical Course
Lecture on Cardiac Failure and arrhythmias
MD405,406 - Introduction to medicine - Postgraduate diploma in
clinical pharmacy - Royal Brisbane Hospital - May
1998
1999:
Clinical tutor for Year 2 Graduate Medical Course
2000-4 : Clinical tutor for Year 1-4 Graduate Medical Course
1997-2013: Preceptor, Graduate School of Medicine, UQ
2009-2013: Preceptor. Griffith University School of Medicine